Âé¶¹´«Ã½
Tag - donanemab
Subscribe
Digital
Print
August 12, 2026
Subscribe
Digital
Print
Yen
Foreign residents
Takaichi
Latest News
Home Delivery
JAPAN
Politics
Society
Crime & Legal
Science & Health
Explainer
History
WORLD
Politics
Crime & Legal
Science & Health
Society
ASIA PACIFIC
Politics
Crime & Legal
Science & Health
Society
BUSINESS
Companies
Economy
Markets
Tech
SPORTS
Sumo
Soccer
Baseball
Basketball
Tennis
Olympics
More sports
OPINION
Editorials
Commentary
Geoeconomic Briefing
Environment
CLIMATE CHANGE
Energy
SUSTAINABILITY
WILDLIFE
EARTH SCIENCE
LIFE
Travel
Digital
Food & Drink
Style & Design
Language
Lifestyle
CULTURE
Film
Books
Music
Art
TV & Streaming
Stage
Entertainment news
COMMUNITY
Voices
Issues
How-tos
Our Lives
My Account
My Bookmarks
Logout
Subscribe for more access
DONANEMAB
JAPAN
/
Science & Health
Jul 21, 2026
Japan scientists identify clusters of protein believed to trigger Alzheimer¡¯s disease
The discovery of a new seed of the amyloid beta protein could lead to early-stage therapy for neurodegenerative disease, according to researchers.
JAPAN
/
Science & Health
Apr 8, 2026
Less than 20% of patients in Japan interested in new Alzheimer¡¯s drugs received one
Many were ineligible or decided against taking the medications due to potential side effects and the high cost, a study has found.
JAPAN
/
Science & Health
/
FOCUS
Sep 17, 2025
Âé¶¹´«Ã½ front-line researchers see bright path ahead for dementia treatment
Four scientists at the forefront of dementia research speak about what kind of future they envision for people with the condition.
JAPAN
/
Science & Health
Nov 13, 2024
Japan OKs insurance coverage of Alzheimer¡¯s drug donanemab
Donanemab became the second Alzheimer¡¯s drug that targets causative deposited plaque in the brain to win the coverage after lecanemab.
WORLD
/
Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer¡¯s drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
JAPAN
/
Science & Health
Aug 2, 2024
Âé¶¹´«Ã½ health ministry set to approve second Alzheimer¡¯s drug
Donanemab, developed by U.S. pharmaceutical firm Eli Lilly, has been backed by a ministry panel.
WHAT¡¯S TRENDING
Editors' Picks
¡®Total whiplash¡¯: Foreign residents react to Âé¶¹´«Ã½ changing permanent residency rules
Yasukuni Shrine introduces ban on military attire and cosplay
Gut bacteria may be behind many of Âé¶¹´«Ã½ colorectal cancer cases
Many Indonesians named after Japanese anime characters
Strong wind and heavy rain forecast as tropical storm approaches Japan
Where do foreign residents in Japan want to die?
¡®Total whiplash¡¯: Foreign residents react to Âé¶¹´«Ã½ changing permanent residency rules
As Âé¶¹´«Ã½ concrete jungles sizzle, urban forestry offers an all-natural fix
Âé¶¹´«Ã½ brewers experiment with a secret ingredient: music
As countries ban social media for children, Japan mulls a different approach
Podcast
Kabukicho: Tokyo¡¯s ¡®stadium of desire¡¯
Longform
What Kumamoto revealed about Âé¶¹´«Ã½ earthquake readiness
By
Alex K.T. Martin
SUSTAINABLE JAPAN
SPECIAL SUPPLEMENTS
Sponsored contents planned and edited by JT Media Enterprise Division.
SUPPLEMENTS BINDER